Literature DB >> 26109399

Management of necrotizing soft tissue infections in the intensive care unit: results of an international survey.

Nicolas de Prost1, Emilie Sbidian, Olivier Chosidow, Christian Brun-Buisson, Roland Amathieu.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26109399     DOI： 10.1007/s00134-015-3916-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  4 in total

1.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.

Authors:  Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Sheldon L Kaplan; Jose G Montoya; James C Wade
Journal:  Clin Infect Dis       Date:  2014-07-15       Impact factor: 9.079

2.  Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections.

Authors:  Jonathan R Carapetis; Peter Jacoby; Kylie Carville; Seong-Jin Joel Ang; Nigel Curtis; Ross Andrews
Journal:  Clin Infect Dis       Date:  2014-04-29       Impact factor: 9.079

3.  Necrotizing soft tissue infections. Risk factors for mortality and strategies for management.

Authors:  D C Elliott; J A Kufera; R A Myers
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

4.  Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review.

Authors:  Dilip Kumar Das; Michael G Baker; Kamalesh Venugopal
Journal:  BMC Infect Dis       Date:  2012-12-12       Impact factor: 3.090
  4 in total
  7 in total

1.  Intensive multidisciplinary management in critical care patients affected by severe necrotizing soft tissue infections: a cooperative method to improve the efficacy of treatment.

Authors:  Milo Gatti; Laura Elisa Gasparini; Matteo Laratta; Anna Sigurtà; Anna Rossi; Paolo Brioschi; Osvaldo Chiara; Chiara Vismara; Francesco Scaglione; Sergio Arlati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-03-06       Impact factor: 3.267

2.  Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial.

Authors:  Martin B Madsen; Peter B Hjortrup; Marco B Hansen; Theis Lange; Anna Norrby-Teglund; Ole Hyldegaard; Anders Perner
Journal:  Intensive Care Med       Date:  2017-04-18       Impact factor: 17.440

3.  Patient's characteristics and outcomes in necrotising soft-tissue infections: results from a Scandinavian, multicentre, prospective cohort study.

Authors:  Martin Bruun Madsen; Steinar Skrede; Anders Perner; Per Arnell; Michael Nekludov; Trond Bruun; Ylva Karlsson; Marco Bo Hansen; Peter Polzik; Morten Hedetoft; Anders Rosén; Edoardo Saccenti; François Bergey; Vitor A P Martins Dos Santos; Anna Norrby-Teglund; Ole Hyldegaard
Journal:  Intensive Care Med       Date:  2019-08-22       Impact factor: 17.440

4.  Therapeutic targets in necrotizing soft tissue infections.

Authors:  Nicolas de Prost; Jeffrey Lipman; Olivier Mimoz
Journal:  Intensive Care Med       Date:  2017-05-04       Impact factor: 17.440

Review 5.  Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review.

Authors:  Jason P Burnham; John P Kirby; Marin H Kollef
Journal:  Intensive Care Med       Date:  2016-10-03       Impact factor: 17.440

6.  Impact of a multidisciplinary care bundle for necrotizing skin and soft tissue infections: a retrospective cohort study.

Authors:  Tomas Urbina; Camille Hua; Emilie Sbidian; Romain Bosc; Françoise Tomberli; Raphael Lepeule; Jean-Winoc Decousser; Armand Mekontso Dessap; Olivier Chosidow; Nicolas de Prost
Journal:  Ann Intensive Care       Date:  2019-10-24       Impact factor: 6.925

Review 7.  Antibiotic Treatment, Mechanisms for Failure, and Adjunctive Therapies for Infections by Group A Streptococcus.

Authors:  Anders F Johnson; Christopher N LaRock
Journal:  Front Microbiol       Date:  2021-11-04       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.